About Us

The Carlat Psychiatry Report (TCPR) is an eight-page monthly newsletter (in both print and online form) that provides clinically relevant, unbiased information on psychiatric practice. We receive no corporate funding, which allows a clear-eyed evaluation of all available treatments. A typical issue (view sample issue) provides:

  • A concise review of a current topic of interest (view past topics)
  • An evaluation of treatment options, including prescription medications, OTCs, and psychotherapies
  • An in-depth interview with a national expert on the issues topic
  • Summaries of the most crucial research findings of the past month

As a subscriber, you will be mailed the printed newsletter each month, and you will have full access to our web site, which allows you to:

  • Read and download the current newsletter before your printed copy arrives
  • Search the entire web site for topics of interest
  • Read and download any past issue from the archives
  • Download concise medication fact sheets with practical pearls (sample)

A regular one-year subscription, including both the printed newsletter and online access, is $109.

TCPR is accredited to provide AMA PRA Category 1 Credit to psychiatrists and CE credit for psychologists.

If you have questions or comments about the Newsletter, please contact us at info@thecarlatreport.com.

History

Dr. Daniel Carlat founded his original CME newsletter, The Carlat Psychiatry Report (TCPR) in January of 2003 as an alternative to existing journals and newsletters that receive pharmaceutical industry funding. It is now the flagship newsletter of Carlat Publishing. Carlat also publishes The Carlat Child Psychiatry Report (CCPR) and The Carlat Behavioral Health Report (TCRBH).

In 2002, Daniel Carlat, MD, a practicing psychiatrist and a writer of psychiatric textbooks, was doing what many of his colleagues were doing in order to make extra money—giving promotional talks for drug companies. At $1000 per engagement, it was easy money, and for a time he was able to convince himself that his talks were completely objective, and were not biased in favor of the funding companies.

One day, however, a regional manager for a major drug company visited Dr. Carlat in his office, saying, “One of my drug reps called me and said that you didn’t seem as enthusiastic about our product as usual at the last lunch. I told him that even Dr. Carlat can’t hit a home run for us every time. Have you been sick?” At that moment, he realized that he had become little more than a glorified pharmaceutical representative. He resigned from all speaker’s bureaus, and started publishing The Carlat Psychiatry Report within six months.

Dr. Carlat started Carlat Publishing, LLC (then called Clearview Publishing, LLC) with $20,000 of his own money. He single-handedly wrote and produced the first few issues during the Tuesdays that he took off from his private practice. Learning about the publishing business on the fly, he mailed out promotional issues by hand, hoping that the idea of an unbiased alternative would gain some traction. Just as his initial capital was running out, subscription checks started flooding in, allowing him to continue printing monthly issues and to gradually hire others to help him with production and writing.

From the beginning, TCPR adopted a skeptical attitude toward many of the marketing claims accompanying new drug launches by pharmaceutical firms. In the January 2004 issue, this approach nearly resulted in the newsletter’s untimely demise. The article in question, entitled “Cymbalta: Double the reuptake, triple the hype,” was critical of some of the statements of efficacy made by Eli Lilly researchers. Soon after the issue was printed, an Eli Lilly attorney contacted the Massachusetts Medical Society (MMS), which was at that time the CME accreditor for the publication. The attorney maintained that the article was unfair and biased, and was therefore out of compliance with ACCME standards for CME programs. MMS ordered the newsletter to cease its CME program pending a formal investigation of the complaint.

Fortunately, Dr. Carlat knew an editor at Lippincott Williams and Wilkins (LWW) who helped facilitate a transfer of the CME program to Wolters Kluwer Health, the parent company of LWW. Thus, the newsletter was able to continue publishing. Dr. Carlat invited Eli Lilly to write a rebuttal to the newsletter’s article on Cymbalta, which was published on the web site. The company did not pursue any legal action against the newsletter.

In July of 2006, Carlat Publishing applied for, and was awarded, independent accreditation as a CME provider by the ACCME.

From the original newsletter (TCPR), Carlat Publishing has continued to grow. Based on the overwhelming success of TCPR and a growing demand from subscribers for more information related to child psychiatry and psychotherapy, the company launched two new newsletters. In May of 2010 the company began publishing The Carlat Child Report (CCPR) and in January 2012 they added The Carlat Behavioral Health Report (TCRBH).

In March 2012, Dr. Carlat took on a new role as the director of the Pew Prescription Project (www.prescriptionproject.org) in Washington, DC. While Dr. Carlat maintains ownership of Carlat Publishing, he has hired a new CEO and other staff to take over management and editorial responsibilities at the company during his tenure at Pew. Carlat Publishing is in a blind trust to prevent any perceived conflicts of interest between Dr. Carlat’s roles at Pew and ownership of the company.